Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華控康泰集團有限公司
Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

PROPOSED ADOPTION OF THE FOURTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY AND CLOSURE OF REGISTER OF MEMBERS

This announcement is made by Kontafarma China Holdings Limited (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

PROPOSED ADOPTION OF THE FOURTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY

The board (the "**Board**") of directors (the "**Directors**") of the Company proposes to amend the third amended and restated memorandum and articles of association of the Company (the "**Memorandum and Articles of Association**") in order to (i) bring the Memorandum and Articles of Association in line with the latest legal and regulatory requirements in relation to electronic dissemination of corporate communications by listed issuers; (ii) provide the Company with flexibility to hold and dispose of the repurchased shares as treasury shares; and (iii) incorporate certain housekeeping amendments (the "**Proposed Amendments**"). In view of the number of the Proposed Amendments, the Board proposes to adopt the fourth amended and restated memorandum and articles of association (the "**New Memorandum and Articles of Association**") (consolidating all the Proposed Amendments) in substitution for and to the exclusion of the Memorandum and Articles of Association.

The Proposed Amendments and proposed adoption of the New Memorandum and Articles of Association is subject to approval of the shareholders of the Company (the "**Shareholders**") by way of special resolution at the forthcoming annual general meeting of the Company (the "**2026 AGM**") currently scheduled to be convened on 5 June 2026.

A circular reflecting, among other matters to be tabled at the 2026 AGM, further details of the Proposed Amendments, the adoption of the New Memorandum and Articles of Association and the notice of the 2026 AGM will be despatched to the Shareholders in due course.

CLOSURE OF REGISTER OF MEMBERS

The 2026 AGM is scheduled to be held on Friday, 5 June 2026. For determining the entitlement to attend and vote at the 2026 AGM, the register of members of the Company will be closed from Monday, 1 June 2026 to Friday, 5 June 2026 (both days inclusive), during which period no transfer of shares will be registered. In order for a Shareholder to be eligible to attend and vote at the 2026 AGM, all transfer forms accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited of 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Friday, 29 May 2026. The record date for determining the eligibility of the Shareholders to attend and vote at the Meeting will be Friday, 5 June 2026.

By order of the Board of
Kontafarma China Holdings Limited
Wang Feifei
Chairman

Hong Kong, 20 April 2026

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Wang Feifei (Chairman and President), Mr. Ge Shouwen (Vice President) and Ms. Guo Zixiu (Financial Controller); one non-executive Director, namely Mr. Huang Yu; and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.